[go: up one dir, main page]

AR127247A1 - Inhibidores de cdk2 de ciclopentilpirazol - Google Patents

Inhibidores de cdk2 de ciclopentilpirazol

Info

Publication number
AR127247A1
AR127247A1 ARP220102682A ARP220102682A AR127247A1 AR 127247 A1 AR127247 A1 AR 127247A1 AR P220102682 A ARP220102682 A AR P220102682A AR P220102682 A ARP220102682 A AR P220102682A AR 127247 A1 AR127247 A1 AR 127247A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
subject
pharmaceutical composition
cdk2
acceptable salt
Prior art date
Application number
ARP220102682A
Other languages
English (en)
Inventor
Jessica Marie Grandner
Kevin M Johnson
Steven Magnuson
Jeremy Mark Murray
Brendan T Parr
Vishal A Verma
Yong Wang
Mingshuo Zeng
Melissa A Ashley
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR127247A1 publication Critical patent/AR127247A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se describen compuestos de fórmula (1) y sales farmacéuticamente aceptables de estos, composiciones farmacéuticas que los comprenden, y sus usos y preparación. Reivindicación 70: Una composición farmacéutica que comprende un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, y un excipiente farmacéuticamente aceptable. Reivindicación 71: Un método para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, en donde el método comprende administrar al sujeto una cantidad terapéuticamente eficaz de un compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70. Reivindicación 74: Un método para elaborar un medicamento para tratar un trastorno mediado por CDK2 en un sujeto que lo necesita, caracterizado porque se usa el compuesto de acuerdo con cualquiera de las reivindicaciones 1 a 69, o una sal farmacéuticamente aceptable de este, o una composición farmacéutica de acuerdo con la reivindicación 70.
ARP220102682A 2021-10-05 2022-10-04 Inhibidores de cdk2 de ciclopentilpirazol AR127247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163252394P 2021-10-05 2021-10-05

Publications (1)

Publication Number Publication Date
AR127247A1 true AR127247A1 (es) 2024-01-03

Family

ID=84245758

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102682A AR127247A1 (es) 2021-10-05 2022-10-04 Inhibidores de cdk2 de ciclopentilpirazol

Country Status (10)

Country Link
US (1) US20240425478A1 (es)
EP (1) EP4412995A1 (es)
JP (1) JP2024538694A (es)
KR (1) KR20240077491A (es)
CN (1) CN118019734A (es)
AR (1) AR127247A1 (es)
AU (1) AU2022360968A1 (es)
CA (1) CA3229067A1 (es)
TW (1) TW202330501A (es)
WO (1) WO2023060057A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308314A (en) 2021-05-07 2024-01-01 Kymera Therapeutics Inc CDK2 compounds and their uses
TW202342002A (zh) * 2022-04-28 2023-11-01 大陸商正大天晴藥業集團股份有限公司 一種吡唑取代環戊酯衍生物及其用途
EP4620954A1 (en) * 2022-11-17 2025-09-24 Shandong Luye Pharmaceutical Co., Ltd. Cdk2 inhibitor, preparation method therefor, and use thereof
WO2025136671A1 (en) * 2023-12-20 2025-06-26 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY210283A (en) * 2019-01-31 2025-09-08 Pfizer 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CN113766125B (zh) 2019-09-29 2022-10-25 Oppo广东移动通信有限公司 对焦方法和装置、电子设备、计算机可读存储介质
CA3210224A1 (en) * 2021-02-12 2022-08-18 Relay Therapeutics, Inc. Cdk inhibitors and methods of use thereof

Also Published As

Publication number Publication date
KR20240077491A (ko) 2024-05-31
EP4412995A1 (en) 2024-08-14
CA3229067A1 (en) 2023-04-13
JP2024538694A (ja) 2024-10-23
CN118019734A (zh) 2024-05-10
WO2023060057A1 (en) 2023-04-13
AU2022360968A1 (en) 2024-02-29
TW202330501A (zh) 2023-08-01
US20240425478A1 (en) 2024-12-26

Similar Documents

Publication Publication Date Title
AR127247A1 (es) Inhibidores de cdk2 de ciclopentilpirazol
CO2023000199A2 (es) Péptidos funcionalizados como agentes antivirales
CL2023001476A1 (es) Nuevos agentes antivirales derivados de la espiropirrolidina
CO2023002852A2 (es) Péptidos funcionalizados como agentes antivirales
CR20230616A (es) Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn)
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
CL2021003202A1 (es) Compuestos de pirrolidina
CO2024001367A2 (es) Compuestos antivirales
AR127501A1 (es) Inhibidores de la proteína que contiene el dominio de prolil hidroxilasa (phd) y usos de los mismos
AR128717A1 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
CO2021014210A2 (es) Compuestos de pirrol
AR129003A1 (es) Compuestos heterocíclicos antivirales
AR128257A1 (es) Compuestos y composiciones para tratar afecciones relacionadas con la actividad de sting
UY39864A (es) Nuevos agentes antivirales derivados de espiropirrolidina
DOP2025000009A (es) Inhibidores de acc novedosos
CL2025000120A1 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b.
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
AR124036A1 (es) Una composición farmacéutica que comprende una sal farmacéuticamente aceptable de [2-(3-fluoro-5-metanosulfonilfenoxi)etil](propilo)amina, y un fármaco farmacéutico para la enfermedad del parkinson y usos de dicha composición
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
CL2025001119A1 (es) Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
CL2024002500A1 (es) Inhibidores de proteínas de unión a emopamilo y usos de estos
AR131503A1 (es) Antagonistas de hpk1 espirocíclicos y usos de los mismos
AR132497A1 (es) Combinación de obicetrapib amorfo e inhibidor de sglt2
GEAP202516786A (en) 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)butan-2-yl)benzamide derivatives as protease inhibitors for treating or preventing coronavirus infection
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello